Two recent publications describe the pharmacological characterization of NLX-112, a potential drug therapy for L-DOPA-induced dyskinesia (LID) in Parkinson's disease. The studies were supported by grants from the Michael J. Fox Foundation (see previous announcement) and show that NLX-112 exhibits potent and complete anti-dyskinetic activity in 'parkinsonian' rats. The activity was maintained upon repeated administration, suggesting a sustained capacity to suppress LID.   Read the full press release:  pdf_symbol

NLX-112, a novel 5-HT1A receptor agonist for the treatment of L-DOPA-induced dyskinesia: Behavioral and neurochemical profile in rat.

Iderberg H, McCreary AC, Varney MA, Kleven MS, Koek W, Bardin L, Depoortère R, Cenci MA, Newman-Tancredi A
Exp Neurol. 2015 May 30. doi: 10.1016/j.expneurol.2015.05.021

The novel 5-HT1A receptor agonist, NLX-112, reduces L-DOPA-induced abnormal involuntary movements in rat: a chronic administration study with microdialysis measurements.

McCreary AC, Varney MA, Newman-Tancredi A
Neuropharmacology. 2016 Jan 8. pii: S0028-3908(16)30013-2. doi: 10.1016/j.neuropharm.2016.01.013.